Muller P, Seeman P
Psychopharmacology (Berl). 1978 Dec 15;60(1):1-11. doi: 10.1007/BF00429171.
It is known that a single dose of a neuroleptic can elicit dopaminergic supersensitivity in animals. On the other hand, the clinical syndrome of tardive dyskinesia takes many months of years to develop. To resolve this apparent discrepancy, it is possible that subclinical or latent tardive dyskinesia is fully compensated in most patients taking neuroleptics. In others, where the tardive dyskinesia is full-blown and grossly apparent, the dopaminergic supersensitivity may be decompensated. Such compensatory and decompensatory phases have been proposed earlier by Hornykiewicz (1974), in the case of Parkinson's Disease. Dopaminergic supersensitivity persists for a period proportional to the lenght of the neuroleptic treatment. It is not yet clear whether the relation between the length of treatment and the persistence of supersensitivity holds for very long treatments, but in principle the relationship might account for the persistence of tardive dyskinesia after years of neuroleptic pretreatment.
已知单剂量的抗精神病药物可在动物中引发多巴胺能超敏反应。另一方面,迟发性运动障碍的临床综合征需要数月甚至数年才会出现。为了解决这一明显的差异,有可能在大多数服用抗精神病药物的患者中,亚临床或潜伏性迟发性运动障碍得到了充分的代偿。而在其他迟发性运动障碍已充分发展且明显可见的患者中,多巴胺能超敏反应可能失代偿。霍尼基维茨(1974年)在帕金森病的案例中更早地提出了这种代偿和失代偿阶段。多巴胺能超敏反应持续的时间与抗精神病药物治疗的时长成正比。目前尚不清楚治疗时长与超敏反应持续时间之间的关系在非常长期的治疗中是否成立,但原则上这种关系可能解释了在多年抗精神病药物预处理后迟发性运动障碍的持续存在。